SMMT: Summit Therapeutics, Inc.
About
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
Current Value
$19.911 Year Return
Current Value
$19.911 Year Return
Key Details
Market Cap
$14.74B
P/E Ratio
-72.25
1Y Stock Return
910.10%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
33.7
Strategies that include SMMT
Stock's related to SMMT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HPQ | 54.45% | $35.53B | +32.29% | 2.99% |
| BURL | 50.11% | $17.44B | +66.00% | 0.00% |
| CRDO | 40.83% | $7.30B | +143.17% | 0.00% |
| BBY | 36.14% | $18.69B | +28.69% | 4.35% |
| AI | 33.93% | $4.19B | +15.61% | 0.00% |
| FENG | 30.97% | $13.37M | +96.77% | 0.00% |
| CMTG | 30.06% | $914.22M | -43.30% | 13.06% |
| BIRK | 29.62% | $8.75B | +7.40% | 0.00% |
| BNTX | 25.72% | $25.51B | +9.51% | 0.00% |
| SSTK | 25.01% | $1.03B | -34.23% | 3.95% |
| WOOF | 24.94% | $1.11B | +4.37% | 0.00% |
| FL | 23.67% | $2.16B | -0.61% | 0.00% |
| SDHC | 21.63% | $1.55B | +43.57% | 0.00% |
| RRGB | 21.30% | $82.67M | -42.73% | 0.00% |
| CLNE | 20.89% | $589.93M | -23.92% | 0.00% |
| FWRD | 20.83% | $998.06M | -46.90% | 0.69% |
| NG | 20.68% | $1.22B | -5.91% | 0.00% |
| KIM | 20.33% | $16.89B | +35.20% | 3.85% |
| NIO | 19.94% | $8.91B | -38.35% | 0.00% |
| XNCR | 19.59% | $1.65B | +27.73% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NFLX | -0.01% | $372.45B | +83.46% | 0.00% |
| CORZ | 0.02% | $4.60B | +3,201.26% | 0.00% |
| ODD | -0.02% | $2.30B | +12.19% | 0.00% |
| TLK | -0.02% | $16.88B | -27.18% | 6.58% |
| ATEC | -0.03% | $1.36B | -16.49% | 0.00% |
| AQB | -0.04% | $3.78M | -37.77% | 0.00% |
| FOUR | 0.04% | $7.17B | +60.36% | 0.00% |
| ZUMZ | -0.04% | $409.63M | +17.32% | 0.00% |
| MYGN | 0.05% | $1.37B | -14.19% | 0.00% |
| ATRO | -0.05% | $575.48M | +5.29% | 0.00% |
| NVMI | 0.05% | $5.16B | +44.02% | 0.00% |
| OFIX | 0.05% | $715.75M | +67.38% | 0.00% |
| WRAP | 0.05% | $62.86M | -49.45% | 0.00% |
| NGL | -0.05% | $572.94M | +5.60% | 0.00% |
| CAPR | 0.06% | $839.37M | +532.19% | 0.00% |
| INFU | 0.06% | $193.50M | -1.62% | 0.00% |
| IMNN | -0.06% | $10.02M | -22.89% | 0.00% |
| ASTS | -0.06% | $4.31B | +506.50% | 0.00% |
| SPOT | -0.06% | $90.80B | +159.59% | 0.00% |
| PLCE | -0.06% | $194.34M | -20.91% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRM | -49.25% | $309.20B | +44.18% | 0.37% |
| PATH | -48.57% | $7.02B | -29.77% | 0.00% |
| NTNX | -44.79% | $18.33B | +70.72% | 0.00% |
| KSS | -38.32% | $1.89B | -25.17% | 11.94% |
| NOAH | -33.64% | $775.22M | -3.69% | 8.96% |
| HRL | -33.05% | $16.30B | -8.38% | 3.81% |
| BBW | -29.61% | $495.83M | +39.52% | 1.63% |
| NOW | -29.08% | $210.55B | +52.92% | 0.00% |
| A | -29.00% | $36.11B | +1.43% | 0.75% |
| DSG | -24.33% | $9.71B | +39.81% | 0.00% |
| HESM | -22.24% | $3.78B | +14.54% | 7.24% |
| IMVT | -18.98% | $3.70B | -23.48% | 0.00% |
| BRKR | -18.43% | $7.31B | -25.31% | 0.39% |
| DOCU | -18.12% | $16.14B | +87.11% | 0.00% |
| CRWD | -17.20% | $86.61B | +69.05% | 0.00% |
| HUBS | -16.82% | $35.23B | +44.73% | 0.00% |
| ADBE | -16.56% | $219.93B | -18.23% | 0.00% |
| BRZE | -15.93% | $3.72B | -30.26% | 0.00% |
| RBRK | -15.92% | $8.03B | +38.16% | 0.00% |
| NET | -15.69% | $33.09B | +30.49% | 0.00% |
ETF's related to SMMT
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FELC | -0.04% | $3.99B | 0.18% |
| DSI | 0.04% | $4.87B | 0.25% |
| FDMO | 0.05% | $365.25M | 0.15% |
| QQQM | 0.09% | $36.44B | 0.15% |
| JBBB | -0.11% | $1.26B | 0.49% |
| WTAI | -0.14% | $192.86M | 0.45% |
| IBMM | -0.14% | $391.28M | 0.18% |
| EIDO | 0.15% | $302.10M | 0.59% |
| IGPT | -0.15% | $407.54M | 0.58% |
| NTSX | -0.15% | $1.18B | 0.2% |
| IBHD | -0.17% | $327.80M | 0.35% |
| KRBN | -0.18% | $242.47M | 0.85% |
| SHV | -0.20% | $18.13B | 0.15% |
| BSCQ | 0.21% | $4.02B | 0.1% |
| HYMU | -0.24% | $232.71M | 0.35% |
| DIA | -0.24% | $38.06B | 0.16% |
| SFLR | 0.27% | $552.90M | 0.89% |
| QQQ | 0.28% | $317.87B | 0.2% |
| FMHI | -0.28% | $747.15M | 0.7% |
| ONEQ | -0.29% | $7.14B | 0.21% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IGV | -20.55% | $9.18B | 0.41% |
| KCCA | -14.10% | $220.51M | 0.87% |
| EQLS | -12.76% | $76.08M | 1% |
| CORN | -12.42% | $61.12M | 0.2% |
| SKYY | -11.01% | $3.41B | 0.6% |
| FTGC | -10.82% | $2.17B | 1.02% |
| GSG | -10.70% | $914.42M | 0.75% |
| COMT | -10.37% | $829.06M | 0.48% |
| PDBC | -10.28% | $4.40B | 0.59% |
| DBC | -10.24% | $1.39B | 0.87% |
| CMDY | -9.63% | $279.14M | 0.28% |
| USCI | -9.55% | $185.47M | 1.07% |
| BCD | -9.55% | $245.02M | 0.3% |
| BCI | -9.46% | $1.20B | 0.26% |
| EZA | -9.45% | $291.73M | 0.59% |
| DBE | -9.43% | $50.13M | 0.77% |
| DUSB | -8.47% | $797.63M | 0.15% |
| WEAT | -8.39% | $120.27M | 0.28% |
| FDN | -8.37% | $6.98B | 0.51% |
| DBO | -8.17% | $217.57M | 0.77% |
News
Yahoo
Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund was down 3.72% for the quarter vs. +2.54% for the MSCI ACWI (in $A). It was down 5.59% in September vs. -0.35% for the index. The market rose in the […]
Yahoo
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Yahoo
With the end of 2024 approaching, what could be more natural than to figure out the top stocks for the rest of the year? Stock picking of this sort is an essential skill for every investor, and fortunately, the Smart Score make it easier. This data gathering and sorting tool from TipRanks uses a combination of AI tech and natural language algorithms to gather and comb through the aggregated data of the stock market – data derived from thousands of traders dealing in thousands of stocks for tens
Yahoo
If you're patient, these businesses have a lot of promising projects in the works.
Yahoo
A cancer drug has vast potential for the company, says a pundit newly following it.
Yahoo
JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones. The analyst says, “We believe Summit shares represent a unique investment opportunity.” Also Read: Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Stu
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.